Every one of those 1 sits in a single category, pharma. Docebo is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. Weatherford International appears in 1 tracked Biotech story from March 8, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Weatherford International
Every one of those 1 sits in a single category, pharma. Docebo is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. Weatherford International appears in 1 tracked Biotech story from March 8, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Weatherford International. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen has upgraded Organogenesis (NASDAQ: ORGO) to a 'Buy' rating, signaling increased confidence in the regenerative medicine specialist's market position. This move comes amid a broader wave of optimistic re-ratings for mid-cap growth stocks across multiple sectors, including oilfield services and software.
Weatherford International is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.